Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 47

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 47
---
(i) . The Company will use the net proceeds from the offering for any corporate purpose at the sole discretion of the Company.

(j) . During the term of this Agreement, the Company shall not enter into, announce or recommend to its shareholders any agreement,
plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability
or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the
Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents.
Notwithstanding the foregoing, the Company shall not be in breach of this section if the Company enters into, announces or recommends
to its shareholders any business combination (or similar) whereby the shareholders of the Company immediately prior to the effective time
of such business combination would own less than a 50.0% of the outstanding shares of the Company immediately following the effective
time of such business combination.

| -24- |

(k) .
From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its commercially
reasonable efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security
or solicit any offers to buy any security, under circumstances that would reasonably be expected to (i) require registration of the offer
and sale by the Company to the Investor of any of the Securities under the Securities Act, or (ii) cause this offering of the Securities
by the Company to the Investor to be integrated with other offerings by the Company in a manner that would require shareholder approval
pursuant to the rules of the Principal Market, unless in the case of this clause and (iii), shareholder approval is obtained before the
closing of such subsequent transaction in accordance with the rules of such Principal Market, if applicable.

(l) . Except as expressly set forth in the Transaction Documents or any other writing to the contrary, each party shall pay
the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation and preparation this Agreement, that on the Execution Date, the Company shall pay a document
preparation fee to the Investor to reimburse up to $35,000 of the Investor’s legal fees.

(m) . The Investor shall have the right to request and receive up to once per fiscal quarter, upon five (